(Beta Cell) Stressing You Out?
You thought that beta cells were passive participants in their own immune-mediated death, leading to type 1 diabetes (T1D)? Wrong.
It’s Official: Teplizumab is Under Review by the FDA
The FDA regulatory review is now under way for teplizumab, to prevent or delay T1D in at-risk individuals. The target action date is July 2, 2021.
Bringing Type 1 Diabetes Screening to the Public
Breakthrough T1D is launching T1Detect, a community-based education and awareness program to expand screening to the general population.
Microbiome Reset: Clinical Trial in Newly Diagnosed Youth
While genetics play a major role in the development of type 1 diabetes (T1D), mounting evidence supports the strong influence of the intestinal environment—called the microbiome—in this disease. Nevertheless, few “microbiome-based” strategies have been tested in clinical trials. Recently, Graciela Lorca, Ph.D., professor of microbiology at the University of Florida, found that one bacterial strain—a […]
Breakthrough T1D Researchers Develop a Combined Risk Score to Predict Which Children Develop T1D
Type 1 diabetes (T1D) can be hard to predict in high risk children. Testing for the presence of T1D autoantibodies—antibodies against one’s own proteins—helps reduce the incidence of diabetic ketoacidosis (DKA)—a common occurrence in children upon diagnosis, that can lead to death if not treated—but this testing is not widely available. While having 2 or […]
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two years—the onset of type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of […]
Dr. Jane Buckner Discusses Hydroxychloroquine T1D Prevention Study
Details about the TrialNet study, including why Hydroxychloroquine, and the status of subject participation.
Public and Private Organizations, All with the Same Goal: End T1D
In this time of great uncertainty, there is some exciting news out of Europe. Innodia, a partnership between public and private entities working together to fund research aimed at biomarker discovery and the prevention of type 1 diabetes (T1D), received an additional €12 million in funding from the European Commission, Breakthrough T1D and the Helmsley […]
A Promising (Preclinical) Vaccine for Type 1 Diabetes
Wouldn’t it be nice if you could take a vaccine in infancy, and type 1 diabetes would not develop? Preclinical research suggests it might not be that far away.
Dr. Carla Greenbaum Talks about T1D TrialNet During the COVID-19 Pandemic
Carla Greenbaum, M.D., chair of TrialNet—an international Breakthrough T1D-supported network that is dedicated to finding cures for type 1 diabetes (T1D)—and a professor at Benaroya Research Institute, discussed T1D research in the time of COVID-19, including what TrialNet is up to, on Breakthrough T1D’s Facebook Live event. She chats about: What do we know now […]
